{"status":"OK","data":{"advertisement":{"id":242493,"title":"Zapytanie Ofertowe 7/FENG-PAN/2024","partial_offer_allowed":false,"publication_date":"2024-02-05","submission_deadline":"2024-03-06 23:59:59","planned_sign_date":null,"supplementary_orders":null,"terms_of_contract_change":"Wszelkie zmiany w umowie, kt\u00f3ra zostanie zawarta w wyniku post\u0119powania, wymagaj\u0105 formy pisemnej, pod rygorem niewa\u017cno\u015bci. \nAll modification to the agreement, which will be concluded as a result of the proceeding, must be in writing under pain of nullity.","created_at":"2024-02-05 18:59:49","modified_at":"2024-03-07 00:00:03","contact_persons":[{"id":3621,"forename":"Ma\u0142gorzata","surname":"S\u0119ktas","phone_number":"+48 22 5936277","email":"m.sektas@cellis.eu","created_by":null,"created_at":"2026-03-20 13:48:06","modified_at":"2026-03-20 13:48:06","modified_by":null}],"orders":[{"id":393321,"estimated_value":null,"order_items":[{"id":443512,"description":"Badanie in vivo na myszach (samicach)z niedoborem odporno\u015bci z implantowanym podsk\u00f3rnie modelem ludzkiego guza trzustki PDX.\nPlanowana data rozpocz\u0119cia realizacji zam\u00f3wienia: 1.09.2025 r.\n\nNa wy\u017cej wymienione zam\u00f3wienie sk\u0142ada si\u0119:\n\u2022\t\u201eBadanie in vivo na myszach (samicach) z niedoborem odporno\u015bci z implantowanym podsk\u00f3rnie modelem ludzkiego guza trzustki PDX,\n\u2022\tPomiar obj\u0119to\u015bci guza,\n\u2022\tPrze\u017cywalno\u015b\u0107 myszy,\n\u2022\t Przygotowanie:\na) protoko\u0142u badania,\nb) opisu badania,\nc) wynik\u00f3w prowadzonych obserwacji z monitorowania i zdrowia zwierz\u0105t (np. masa cia\u0142a) i pomiaru wzrostu guza.\nWy\u017cej wymienione dokumenty nale\u017cy sporz\u0105dzi\u0107 wy\u0142\u0105cznie w wersji elektronicznej.\nOpis bada\u0144:\n- myszy z niedoborem odporno\u015bci z podsk\u00f3rnie wszczepionymi guzami trzustki PDX (pochodz\u0105cymi\nod pacjent\u00f3w) leczone makrofagami za\u0142adowanymi lekiem,\n- czas trwania leczenia: 28 dni, czas trwania obserwacji: maksymalnie 140 dni,\n- wykorzystanie samic myszy,\n- wiek myszy: 6-8 tygodni,\n- spos\u00f3b podawania: dootrzewnowy lub doguzowy (makrofagi), do\u017cylny (lek w grupach standardowej terapii), dootrzewnowy lub doustny (PBS/DPBS),\n- dawkowanie \u2013 do ustalenia,\n- pomiar wzrostu obj\u0119to\u015bci guza i prze\u017cywalno\u015bci myszy do maksymalnie 140 dni od implantacji,\n- liczba myszy w grupie: 10,\n- liczba grup: 4 tj.:\nGrupa 1 \u2013 no\u015bnik leku \u2013 PBS/DPBS,\nGrupa 2 \u2013 makrofagi za\u0142adowane lekiem,\nGrupa 3 \u2013 standardowe leczenie (Standard of Care, np. Gemcytabina),\nGrupa 4 \u2013 makrofagi za\u0142adowane lekiem + standardowe leczenie (np. Gemcytabina).\n\nCel bada\u0144: okre\u015blenie skuteczno\u015bci terapii \u2013 czas prze\u017cycia myszy w poszczeg\u00f3lnych grupach, pomiar\nwzrostu obj\u0119to\u015bci guza.\nZamawiaj\u0105cy dostarczy makrofagi za\u0142adowane lekiem (substancja czynna o podwy\u017cszonym poziomie ryzyka).\nWykonawca powinien zapewni\u0107 uznane modele PDX ludzkiego nowotworu trzustki.\n\nOstateczny zakres zapytania ofertowego b\u0119dzie uzale\u017cniony od rozwoju projektu i b\u0119dzie wynika\u0142 \nz aktualnych potrzeb Zamawiaj\u0105cego. Zamawiaj\u0105cy zastrzega sobie mo\u017cliwo\u015b\u0107 realizacji zam\u00f3wienia \nw jakiejkolwiek cz\u0119\u015bci, a Wykonawcy nie przys\u0142uguj\u0105 z tego tytu\u0142u \u017cadne roszczenia.\n\nIn vivo study on immunodeficient (female) mice with a subcutaneously implanted PDX human pancreatic tumor model. \n\nPlanned date of starting of the order: September 01, 2025.\n\nThe above-mentioned order consist of:\n\u2022\t\u201eIn vivo study on immunodeficient (female) mice with a subcutaneously implanted PDX human pancreatic tumor model,\n\u2022\tTumor volume measurements,\n\u2022\tAnalysis of mice survival,\n\u2022\tPreparing:\na) protocol of the study,\nb) description of the study,\nc) observations from the monitoring of tumor growth and animal health (such as body weights).\nAbove documents should be prepared only in an electronic version.\nStudy details:\n- immunodeficient mice with subcutaneously implanted PDX pancreatic tumors (derived from\nfrom patients) treated with drug-loaded macrophages.\n- treatment duration: 28 days, observation period: maximum of 140 days \n- using female mice,\n- age of the mouse: approx. 6-8 weeks,\n- route of administration of therapy: intraperitoneal or intratumoral (macrophages), intravenous (drug in standard therapy groups), intraperitoneal or oral (PBS/DPBS),\n- dosage \u2013 to be determined,\n- measurement of tumor volume growth and mouse survival up to a maximum of 140 days after implantation,\n- number of mice in the group: 10\n- number of groups: 4, i.e.: \nGroup 1 \u2013 drug carrier, PBS/DPBS\nGroup 2 \u2013 drug-loaded macrophages\nGroup 3 \u2013 standard treatment (SoC, Gemcitabine),\nGroup 4 \u2013 drug-loaded macrophages+ SoC (Gemcitabine).\n\nGoal of the study: evaluation of the effectiveness of therapy \u2013 survival time of mice in each group, measurement of the tumor volume.\n\nThe Ordering Party will deliver prepared drug-loaded macrophages (active substance with an increased level of risk).\n\nContractor should provide PDX models of human pancreatic cancer. \n\nThe final scope of the request for quotation will depend on the development of the project \nand will result from the current needs of the Ordering Party. \nThe Ordering Party reserves the right to complete the order in any part, and the Contractor is not entitled to any claims in this respect.\n","warranty_period":null,"cpv_items":[{"id":8513,"code":"73100000-3","name":"Us\u0142ugi badawcze i eksperymentalno-rozwojowe"}],"timetable_items":[],"fulfillment_places":[{"country":"Polska","voivodeship":null,"poviat":null,"commune":null,"locality":null,"created_by":null,"created_at":"2024-02-05 18:59:49","modified_at":"2024-02-05 18:59:49","modified_by":null,"id":496990,"type":{"id":2,"name":"ca\u0142a Polska"},"group_uuid":"f62c0d09-6613-4e73-aea5-5ab268f00cd9"}],"participation_conditions":[{"id":1213307,"description":"Wykonawca musi posiada\u0107 niezb\u0119dn\u0105 wiedz\u0119 i do\u015bwiadczenie, w tym:\na) udokumentowane do\u015bwiadczenie w prowadzeniu eksperyment\u00f3w na modelach raka trzustki, potwierdzone przez udzia\u0142 w co najmniej dw\u00f3ch projektach/zam\u00f3wieniach w przeci\u0105gu ostatnich dw\u00f3ch lat, \nb) do\u015bwiadczenie w wykonywaniu bada\u0144 przedklinicznych dla partner\u00f3w komercyjnych.\n\nThe Contractor must have the necessary knowledge and experience, including:\na) documented experience in conducting experiments on pancreatic cancer models, confirmed by participation in at least two projects/orders within the last two years,\nb) experience in performing preclinical studies for commercial partners.","type":{"id":2,"name":"Wiedza i do\u015bwiadczenie"},"created_by":null,"created_at":"2024-02-05 18:59:49","modified_at":"2024-02-05 18:59:49","modified_by":null,"group_uuid":"db2a9d5a-b347-492b-8799-078931e8c072"},{"id":1213308,"description":"Wykonawca musi posiada\u0107 potencja\u0142 techniczny, w tym: \na) BioBank pr\u00f3bek ludzkiego raka trzustki (PDX) z mo\u017cliwo\u015bci\u0105 ich hodowli w myszach z niedoborem odporno\u015bci,\nb) zwierz\u0119tarni\u0119 w wysokim standzie czysto\u015bci \nc) laboratoriom wyposa\u017cone w aparatur\u0119 niezb\u0119dn\u0105 do wykonania zam\u00f3wienia w tym:\n- mo\u017cliwo\u015b\u0107 obrazowania przy\u017cyciowo luminescencji ma\u0142ych zwierz\u0105t),\n- mo\u017cliwo\u015b\u0107 przy\u017cyciowego obrazowania wzrostu raka trzustki za pomoc\u0105 MRI lub odpowiednika,\nd) w pe\u0142ni wyposa\u017cone laboratorium hodowli kom\u00f3rkowych.\n\nThe contractor must have technical potential, including:\na) Biobank of human pancreatic cancer samples (PDX) with the possibility of culturing them in immunodeficient mice,\nb) animal facility in a high standard of cleanliness\nc) laboratories equipped with equipment necessary to perform the order, including:\n- possibility of intravital imaging of luminescence of small animals),\n- possibility of intravital imaging of pancreatic cancer growth using MRI or equivalent,\nd) a fully equipped cell culture laboratory.","type":{"id":3,"name":"Potencja\u0142 techniczny"},"created_by":null,"created_at":"2024-02-05 18:59:49","modified_at":"2024-02-05 18:59:49","modified_by":null,"group_uuid":"28ac621f-daf8-483b-9110-6f722cb0a2ad"},{"id":1213309,"description":"1. Ka\u017cdy Oferent mo\u017ce z\u0142o\u017cy\u0107 jedn\u0105 ofert\u0119.\n2. Oferta musi by\u0107 z\u0142o\u017cona na formularzu ofertowym (Za\u0142\u0105cznik 1 do Zapytania Ofertowego nr 7/FENG-PAN/2024). Oferta musi by\u0107 parafowana i podpisana przez nale\u017cycie umocowanego przedstawiciela Oferenta. W przypadku podpisania oferty przez osob\u0119 niewymienion\u0105 w dokumencie rejestrowym (ewidencyjnym) Oferenta, nale\u017cy do oferty do\u0142\u0105czy\u0107 stosowne pe\u0142nomocnictwo.\n3. Oferent zobowi\u0105zany jest z\u0142o\u017cy\u0107 wraz z ofert\u0105 aktualny odpis z krajowego rejestru s\u0105dowego lub z centralnej ewidencji i informacji o dzia\u0142alno\u015bci gospodarczej, wystawiony nie wcze\u015bniej ni\u017c trzy (3) miesi\u0105ce przed up\u0142ywem terminu sk\u0142adania ofert, w celu wykazania braku podstaw do wykluczenia. \n\n1. Each Bidder may submit only one offer.\n2. Offer should be prepared in the bid form (Appendix 1 to the Request for Quotation no. 7/FENG-PAN/2024). The offer must be initialled and signed by the authorised representative of the Bidder.\nIf the offer would be signed by the person not listed in registered documents of the Contractor, the offer shall be accompanied by the appropriate power of attorney.\n3. Offer must include all attachments required by the Ordering Party confirmed to be true \nby the authorised representative of the Bidder.\n4. Contractor must submit with the offer copy (scan) of relevant Register of Business Activity, applicable to country of residence of Contractor, issued not earlier than three (3) months before the deadline for submission the offer to demonstrate the absence of grounds for exclusion.","type":{"id":6,"name":"Lista wymaganych dokument\u00f3w/o\u015bwiadcze\u0144"},"created_by":null,"created_at":"2024-02-05 18:59:49","modified_at":"2024-02-05 18:59:49","modified_by":null,"group_uuid":"966f7abc-1a1d-4b75-bbdd-1961401f4bb5"},{"id":1213310,"description":"Wykonawca nie mo\u017ce by\u0107 powi\u0105zany osobowo lub kapita\u0142owo z Zamawiaj\u0105cym. \nPrzez powi\u0105zania kapita\u0142owe lub osobowe rozumie si\u0119 wzajemne powi\u0105zania mi\u0119dzy beneficjentem \nlub osobami upowa\u017cnionymi do zaci\u0105gania zobowi\u0105za\u0144 w imieniu beneficjenta lub osobami wykonuj\u0105cymi w imieniu beneficjenta czynno\u015bci zwi\u0105zane z przeprowadzeniem procedury wyboru wykonawcy a wykonawc\u0105, polegaj\u0105ce w szczeg\u00f3lno\u015bci na:\na)\tuczestniczeniu w sp\u00f3\u0142ce jako wsp\u00f3lnik sp\u00f3\u0142ki cywilnej lub sp\u00f3\u0142ki osobowej,\nb)\tposiadaniu co najmniej 10% udzia\u0142\u00f3w lub akcji, o ile ni\u017cszy pr\u00f3g nie wynika z przepis\u00f3w prawa,\nc)\tpe\u0142nieniu funkcji cz\u0142onka organu nadzorczego lub zarz\u0105dzaj\u0105cego, prokurenta, pe\u0142nomocnika\nd)\tpozostawaniu w zwi\u0105zku ma\u0142\u017ce\u0144skim, w stosunku pokrewie\u0144stwa lub powinowactwa w linii prostej, pokrewie\u0144stwa drugiego stopnia lub powinowactwa drugiego stopnia w linii bocznej \nlub w stosunku przysposobienia, opieki lub kurateli albo pozostawaniu we wsp\u00f3lnym po\u017cyciu \nz wykonawc\u0105, jego zast\u0119pc\u0105 prawnym lub cz\u0142onkami organ\u00f3w zarz\u0105dzaj\u0105cych lub organ\u00f3w nadzorczych wykonawc\u00f3w ubiegaj\u0105cych si\u0119 o udzielenie zam\u00f3wienia, \ne)\tpozostawaniu z wykonawc\u0105 w takim stosunku prawnym lub faktycznym, \u017ce istnieje uzasadniona w\u0105tpliwo\u015b\u0107 co do ich bezstronno\u015bci lub niezale\u017cno\u015bci w zwi\u0105zku z post\u0119powaniem o udzielenie zam\u00f3wienia.\nOferent zobowi\u0105zany jest z\u0142o\u017cy\u0107 stosowne o\u015bwiadczenie zawarte w Za\u0142\u0105czniku 3 do Zapytania Ofertowego nr 7/FENG-PAN/2024.\n\nThe Contractor may not be personally, or equity related to the Ordering Party.\nEquity or personal relationship is understood as relations between the Ordering Party or individuals authorized to take commitments on behalf of the Ordering Party or those acting on behalf of the Ordering Party in order to prepare and implement the contract award procedure, and the Contractor, including in particular:\na)\tBeing a partner to civil law partnership or commercial law partnership,\nb)\tHolding at least 10% of shares, if lower threshold does not result from law,\nc)\tBeing a member of a supervisory or management corporate body, a holder of general commercial power of attorney, an authorised representative,\nd)\tBeing married to, being in direct consanguinity or affinity, second degree consanguinity or affinity \nof the second degree collaterally or by adoption or guardianship or being in cohabitation with the Contractor, its legal representative or members of management or supervisory bodies of economic operators competing for the contract award,\ne)\tbeing in such a legal or factual relationship with the Contractor that there is a reasonable doubt as to their impartiality or independence in connection with the contract award procedure.\n\nThe Bidder is obliged to submit a relevant statement contained in Annex 3 to the Request for Quotation no. 7/FENG-PAN/2024.","type":{"id":7,"name":"Dodatkowe warunki udzia\u0142u"},"created_by":null,"created_at":"2024-02-05 18:59:49","modified_at":"2024-02-05 18:59:49","modified_by":null,"group_uuid":"a69660d9-0aa1-4fa1-8cb4-49a02f2923ed"}],"category":{"id":1,"name":"Us\u0142uga"},"subcategory":{"id":4,"name":"Us\u0142ugi badawcze"},"created_by":null,"created_at":"2024-02-05 18:59:49","modified_at":"2024-02-05 18:59:49","modified_by":null,"group_uuid":"4af6d5ff-62ed-43d8-a3ae-6d7939ea9c14"}],"evaluation_criteria":[{"id":675516,"price_criterion":true,"description":"\u2022\tCena \u2013 80 %\nKryterium \u201eCena\u201d oceniane b\u0119dzie nast\u0119puj\u0105co: \nPi(C) \u2013 liczba punkt\u00f3w jakie otrzyma oferta \u201ei\u201d za kryterium \u201eCena\u201d\nCmin \u2013 najni\u017csza cena spo\u015br\u00f3d wszystkich wa\u017cnych i nieodrzuconych ofert\nCi \u2013 cena oferty \u201ei\u201d \nPi(C) = (Cmin : Ci) x 80\nW kryterium \u201eCena\u201d Oferent mo\u017ce uzyska\u0107 80 pkt.","created_by":null,"created_at":"2024-02-05 18:59:49","modified_at":"2024-02-05 18:59:49","modified_by":null,"group_uuid":"bab68b95-96ec-45b2-924a-bac644f03d37"},{"id":675517,"price_criterion":false,"description":"\u2022\tTermin wykonania us\u0142ugi \u2013 20%\nKryterium to nale\u017cy rozumie\u0107, jako gotowo\u015b\u0107 do rozpocz\u0119cia badania od dnia otrzymania zlecenia od Zamawiaj\u0105cego i oceniane b\u0119dzie nast\u0119puj\u0105co:\nponi\u017cej 4 tygodni \u2013 20 pkt,\n4 tygodnie i powy\u017cej \u2013 0 pkt.\nOferent mo\u017ce uzyska\u0107 w tym kryterium 20 punkt\u00f3w.","created_by":null,"created_at":"2024-02-05 18:59:49","modified_at":"2024-02-05 18:59:49","modified_by":null,"group_uuid":"7b60d311-2002-45bc-9f67-d33eb75bd386"}],"is_variant":false,"title":"Badanie in vivo na myszach","order_node":{"id":298353},"created_by":null,"created_at":"2024-02-05 18:59:49","modified_at":"2024-02-05 18:59:49","modified_by":null}],"created_by":{"id":4346,"contact_persons":[]},"modified_by":{"modified_by":null,"id":1,"contact_persons":[]},"status":{"id":2,"label":"PUBLISHED","name":"Opublikowane"},"advertiser_address_details":{"name":"Cellis Sp. z o.o.","identification_number_type":"nip","identification_number":"5252640606","address":{"country":"Polska","voivodeship":"mazowieckie","poviat":"Warszawa","commune":"\u017boliborz","locality":"Warszawa","created_by":null,"created_at":null,"modified_at":null,"modified_by":null,"id":644859,"street":"Genera\u0142a Zaj\u0105czka","number_description":"28","postcode":"01-510"},"created_by":{"id":4346,"contact_persons":[]},"created_at":"2024-02-05 18:59:48","modified_at":"2024-02-05 18:59:48","modified_by":{"id":4346,"contact_persons":[]},"id":243049},"advertisement":{"id":184508,"number":"2024-4346-184508","publication_date":"2024-02-05","created_by":{"id":4346,"contact_persons":[]},"created_at":"2024-02-05 18:59:48","modified_at":"2024-03-07 00:00:03","modified_by":{"modified_by":null,"id":1,"contact_persons":[]},"status":{"id":6,"label":"RESOLVED","name":"Rozstrzygni\u0119te"},"all_available_version_ids":[242493],"enrollment":{"id":43421,"name":"Kom\u00f3rkowa terapia raka trzustki","number":"005/23","activity":{"created_by":null,"created_at":"2023-02-01 09:22:25","modified_at":"2023-02-01 09:22:25","modified_by":null},"region":null,"institution":{"created_by":null,"created_at":"2023-02-01 09:27:55","modified_at":"2023-02-01 09:27:55","modified_by":null},"full_number":"FENG.01.01-IP.01-005/23","perspective":{},"programme":{"created_by":null,"created_at":"2023-02-01 09:21:41","modified_at":"2023-02-01 09:21:41","modified_by":null},"priority":{"created_by":null,"created_at":"2023-02-01 09:21:51","modified_at":"2023-02-01 09:21:51","modified_by":null},"type":"enrollment","created_by":null,"created_at":"2024-01-05 16:18:59","modified_at":"2024-01-05 16:18:59","modified_by":null},"projects":[],"is_author":false,"is_admin":false},"attachments":[{"origin":{"id":242493,"publication_date":"2024-02-05"},"id":1239389,"name":"PRZED ZMIANAMI-Zapytanie ofertowe 7/FENG-PAN/2024","file":{"id":1381456,"name":"7_FENG-PAN_2024_ przed zmianami.pdf","created_at":"2024-02-05 18:55:53","created_by":{"forename":"Ma\u0142gorzata","surname":"S\u0119ktas"},"uri":"/api/files/1381456"},"group_uuid":"435437f5-48a7-4d13-9007-d0ba1651ba2d"},{"origin":{"id":242493,"publication_date":"2024-02-05"},"id":1239390,"name":"BEFORE CHANGES-Request for Quotation 7/FENG-PAN/2024","file":{"id":1381458,"name":"Request for quotation_7FENG-PAN_before changes.pdf","created_at":"2024-02-05 18:56:14","created_by":{"forename":"Ma\u0142gorzata","surname":"S\u0119ktas"},"uri":"/api/files/1381458"},"group_uuid":"8c3180a0-f8fc-4c05-bb5e-120a059c0085"},{"origin":{"id":242493,"publication_date":"2024-02-05"},"id":1239391,"name":"ZMIANY (CHANGES) do Zapytania Ofertowego 7/FENG-PAN/2024 05.02.2024","file":{"id":1381460,"name":"Zmiana do zapytania 7_FENG-PAN_2024_05.02.2024.pdf","created_at":"2024-02-05 18:56:43","created_by":{"forename":"Ma\u0142gorzata","surname":"S\u0119ktas"},"uri":"/api/files/1381460"},"group_uuid":"a0b33f06-fb6a-406d-9782-b0f5f6e9ad74"},{"origin":{"id":242493,"publication_date":"2024-02-05"},"id":1239392,"name":"PO ZMIANACH-Zapytanie Ofertowe 7/FENG-PAN/2024_05.02.2024","file":{"id":1381462,"name":"7_FENG-PAN_2024_po zmianach.pdf","created_at":"2024-02-05 18:58:31","created_by":{"forename":"Ma\u0142gorzata","surname":"S\u0119ktas"},"uri":"/api/files/1381462"},"group_uuid":"da282f18-7d6e-4f10-b818-db3f4b7e3611"},{"origin":{"id":242493,"publication_date":"2024-02-05"},"id":1239393,"name":"AFTER CHANGES-Request of Quotation 7/FENG-PAN/2024_05.02.2024","file":{"id":1381463,"name":"Request for quotation_7_FENG_PAN_after changes.pdf","created_at":"2024-02-05 18:59:12","created_by":{"forename":"Ma\u0142gorzata","surname":"S\u0119ktas"},"uri":"/api/files/1381463"},"group_uuid":"b46179c7-3048-4bee-a7e5-18b8d890530c"}]},"dictionaries":{"announcement_status_draft":1,"announcement_status_published":2},"favorite":null,"badge":null,"offer_set_badge_count":null,"question_badge_count":null}}